Generic placeholder image

Current Cancer Drug Targets

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Non-Homologous DNA End Joining in Anticancer Therapy

Author(s): Elzbieta Pastwa and Mariusz Malinowski

Volume 7 , Issue 3 , 2007

Page: [243 - 250] Pages: 8

DOI: 10.2174/156800907780618284

Price: $65

Abstract

Non-homologous DNA end joining (NHEJ) is the major pathway for the repair of double-strand breaks (DSBs) in human cells. Proteins involved in NHEJ pathway can become molecular targets in the treatment of cancer. Inhibition of this pathway leads to radio- and chemosensitization of cancer cells. This review will focus on the new therapeutic strategies for NHEJ pathway inhibition and their application in anticancer therapy.

Keywords: Non-homologous DNA end joining, NHEJ, DNA double-strand breaks, DSBs, DNA-dependent protein kinase, DNA-PK, chemosensitization, radiosensitization


Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy